To the Editor:Testicular tumor represents 1%of male neoplasms and 5%of urogenital tumors.Non-seminomatous germ cell tumor(NSGCT)accounts for nearly 40%of all testicular cancers.The survival of patients with NSGCT has ...To the Editor:Testicular tumor represents 1%of male neoplasms and 5%of urogenital tumors.Non-seminomatous germ cell tumor(NSGCT)accounts for nearly 40%of all testicular cancers.The survival of patients with NSGCT has been improved because of advanced multimodal therapies(orchiectomy,and if necessary,subsequent chemotherapy).[1]However,to the best of our knowledge,survival of NSGCT patients has not been studied in a large Chinese cohort yet.Therefore,this study assessed the clinical characteristics,treatments,and outcomes of patients with NSGCT.展开更多
基金funded by the National Natural Science Foundation of China(Nos.81370855,81770857,and 81200551)the Project of Sichuan Province Science and Technology Department(Nos.2015SZ0230 and 2017KJT0034).
文摘To the Editor:Testicular tumor represents 1%of male neoplasms and 5%of urogenital tumors.Non-seminomatous germ cell tumor(NSGCT)accounts for nearly 40%of all testicular cancers.The survival of patients with NSGCT has been improved because of advanced multimodal therapies(orchiectomy,and if necessary,subsequent chemotherapy).[1]However,to the best of our knowledge,survival of NSGCT patients has not been studied in a large Chinese cohort yet.Therefore,this study assessed the clinical characteristics,treatments,and outcomes of patients with NSGCT.
